Randomisierte kontrollierte Studie
Efficacy and Safety of Water-Free Lipid Formulation System Containing Calcipotriol Against Psoriasis Vulgaris
Journal of Drugs in Dermatology · 2023
DOI: 10.36849/jdd.7151 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Drugs in Dermatology, 2023. Verfasst von Jan Holmback und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Dermatologic Agents, Psoriasis, Drug-Related Side Effects and Adverse Reactions.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Dermatologic AgentsPsoriasisDrug-Related Side Effects and Adverse ReactionsHumansOintmentsTreatment OutcomeCalcitriolEmollients
Substanzen
calcipotrieneDermatologic AgentsOintmentsCalcitriolEmollients
Zitieren
APA
Holmback, J., Carlsson, A., & Rinwa, P. (2023). Efficacy and Safety of Water-Free Lipid Formulation System Containing Calcipotriol Against Psoriasis Vulgaris. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.7151
Vancouver
Holmback J, Carlsson A, Rinwa P. Efficacy and Safety of Water-Free Lipid Formulation System Containing Calcipotriol Against Psoriasis Vulgaris. Journal of Drugs in Dermatology. 2023. doi:10.36849/jdd.7151
BibTeX
@article{Holmback2023,
author = {Holmback, Jan and Carlsson, Anders and Rinwa, Puneet},
title = {Efficacy and Safety of Water-Free Lipid Formulation System Containing Calcipotriol Against Psoriasis Vulgaris},
journal = {Journal of Drugs in Dermatology},
year = {2023},
doi = {10.36849/jdd.7151}
}
EUVIMED